Q2 2018 EPS Estimates for Insulet Corporation Increased by Northcoast Research (NASDAQ:PODD)

Insulet Corporation (NASDAQ:PODD) – Stock analysts at Northcoast Research raised their Q2 2018 earnings per share estimates for shares of Insulet Corporation in a research note issued to investors on Friday. Northcoast Research analyst E. Snyder now forecasts that the medical instruments supplier will post earnings of $0.00 per share for the quarter, up from their prior forecast of ($0.01).

Insulet Corporation (NASDAQ:PODD) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). Insulet Corporation had a negative return on equity of 46.88% and a negative net margin of 7.30%. The company had revenue of $110 million during the quarter, compared to analyst estimates of $106.23 million. During the same quarter in the previous year, the company posted ($0.08) EPS. Insulet Corporation’s revenue for the quarter was up 26.0% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: This report was posted by Markets Daily and is owned by of Markets Daily. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/08/08/q2-2018-eps-estimates-for-insulet-corporation-increased-by-northcoast-research-nasdaqpodd.html.

Other research analysts also recently issued research reports about the stock. B. Riley reaffirmed a “neutral” rating and issued a $44.00 price target on shares of Insulet Corporation in a report on Tuesday, May 9th. Oppenheimer Holdings, Inc. set a $55.00 price target on shares of Insulet Corporation and gave the company a “hold” rating in a report on Friday. BTIG Research raised shares of Insulet Corporation from a “neutral” rating to a “buy” rating and set a $47.00 price target for the company in a report on Wednesday, May 10th. William Blair reaffirmed an “outperform” rating on shares of Insulet Corporation in a report on Thursday, May 25th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $50.00 price target (up previously from $42.00) on shares of Insulet Corporation in a report on Tuesday, July 11th. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $49.69.

Insulet Corporation (NASDAQ PODD) traded up 1.54% during midday trading on Monday, hitting $54.71. The stock had a trading volume of 75,254 shares. The stock’s 50-day moving average is $50.00 and its 200-day moving average is $44.62. The company’s market capitalization is $3.17 billion. Insulet Corporation has a 1-year low of $30.69 and a 1-year high of $54.85.

In other news, Director Jessica Hopfield acquired 2,580 shares of the firm’s stock in a transaction on Thursday, May 11th. The stock was acquired at an average price of $38.68 per share, with a total value of $99,794.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael P. Spears acquired 2,500 shares of the firm’s stock in a transaction on Tuesday, May 16th. The stock was purchased at an average cost of $40.59 per share, with a total value of $101,475.00. The disclosure for this purchase can be found here. In the last three months, insiders acquired 8,080 shares of company stock valued at $317,339. 2.60% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the company. Prudential Financial Inc. increased its stake in shares of Insulet Corporation by 42.0% in the second quarter. Prudential Financial Inc. now owns 8,282 shares of the medical instruments supplier’s stock valued at $425,000 after buying an additional 2,450 shares during the last quarter. Geneva Advisors LLC increased its stake in shares of Insulet Corporation by 2.3% in the second quarter. Geneva Advisors LLC now owns 22,215 shares of the medical instruments supplier’s stock valued at $1,140,000 after buying an additional 504 shares during the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of Insulet Corporation during the second quarter valued at about $8,882,000. Turner Investments LLC purchased a new stake in shares of Insulet Corporation during the second quarter valued at about $334,000. Finally, Frontier Capital Management Co. LLC increased its stake in shares of Insulet Corporation by 2.8% in the second quarter. Frontier Capital Management Co. LLC now owns 1,809,473 shares of the medical instruments supplier’s stock valued at $92,844,000 after buying an additional 50,019 shares during the last quarter.

Insulet Corporation Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Earnings History and Estimates for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply